{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:52:43Z","timestamp":1790952763486,"version":"4.1.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"am","delay-in-days":286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014039","name":"US Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-19-1-0720"],"award-info":[{"award-number":["W81XWH-19-1-0720"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-18-1-0618"],"award-info":[{"award-number":["W81XWH-18-1-0618"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217986","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T06:34:35Z","timestamp":1754980475000},"page":"217986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer"],"prefix":"10.1016","volume":"632","author":[{"given":"Leah","family":"Tharian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9492-3249","authenticated-orcid":false,"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000519861","article-title":"Metastatic prostate cancer: treatment options","volume":"100","author":"Achard","year":"2022","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.canlet.2025.217986_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ucl.2017.07.008","article-title":"Newly diagnosed metastatic prostate cancer: has the paradigm changed?","volume":"44","author":"Damodaran","year":"2017","journal-title":"Urol. Clin.North Am"},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","article-title":"Biological evolution of castration-resistant prostate cancer","volume":"5","author":"Davies","year":"2019","journal-title":"Eur. Urol. Focus"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with No metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2025.217986_bib8","article-title":"Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217986_bib9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/diagnostics13091661","article-title":"Trends in the use of second-generation androgen receptor axis inhibitors for metastatic hormone-sensitive prostate cancer and clinical factors predicting biological recurrence","volume":"13","author":"Nakane","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"issue":"28","key":"10.1016\/j.canlet.2025.217986_bib11","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.prro.2022.03.004","article-title":"Radium-223 for metastatic castrate-resistant prostate cancer","volume":"12","author":"Sindhu","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.canlet.2025.217986_bib13","article-title":"Dose-dense docetaxel and Radium-223 in bone-dominant metastatic castration-resistant prostate cancer","volume":"29","author":"Connell","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41391-022-00493-x","article-title":"Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at dana farber and in the PROCEED registry","volume":"25","author":"Wei","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217986_bib17","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2021.1912015","article-title":"Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer","volume":"22","author":"Maughan","year":"2021","journal-title":"Expet Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.canlet.2025.217986_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.23765","article-title":"Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer","volume":"79","author":"Petrylak","year":"2019","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.123.265414","article-title":"[177Lu]Lu-PSMA-Radioligand therapy efficacy outcomes in taxane-na\u00efve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review and Meta analysis","volume":"64","author":"Satapathy","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.canlet.2025.217986_bib23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/cells12121606","article-title":"Recent advances in CAR-based solid tumor immunotherapy","volume":"12","author":"Shin","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hoc.2023.05.009","article-title":"Chimeric antigen receptor T-Cell therapy for solid tumors","volume":"37","author":"Wala","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"7","key":"10.1016\/j.canlet.2025.217986_bib25","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"issue":"7949","key":"10.1016\/j.canlet.2025.217986_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance, and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217986_bib28","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/erm.2021.32","article-title":"Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours","volume":"24","author":"Mao","year":"2022","journal-title":"Expet Rev. Mol. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217986_bib29","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/bit.28753","article-title":"Reinforcement learning-guided control strategies for CAR T-cell activation and expansion","volume":"121","author":"Ferdous","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.canlet.2025.217986_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-030-96376-7_10","article-title":"The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells","volume":"183","author":"Gao","year":"2022","journal-title":"Cancer Treat Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib31","first-page":"265","article-title":"Multi-targeting CAR-T cell strategies to overcome immune evasion in lymphoid and myeloid malignancies","volume":"48","author":"Peter","year":"2025","journal-title":"Oncol. Res. Treat."},{"issue":"14","key":"10.1016\/j.canlet.2025.217986_bib32","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217986_bib34","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2025.217986_bib35","article-title":"CD20+CD22+ADAM28+ B cells in tertiary lymphoid structures promote immunotherapy response","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: co-Transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of Non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2025.217986_bib37","article-title":"Ligand-based CAR-T cell: different strategies to drive T cells in future new treatments","volume":"13","author":"Ram\u00edrez-Chac\u00f3n","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib38","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers15061791","article-title":"The BAFF-APRIL system in cancer","volume":"15","author":"Ullah","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib39","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.canlet.2025.217986_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf0108","article-title":"\u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer","volume":"9","author":"Frieling","year":"2023","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib43","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/cells9061337","article-title":"Transposon-based CAR T cells in acute leukemias: where are we going?","volume":"9","author":"Magnani","year":"2020","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.canlet.2025.217986_bib44","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"key":"10.1016\/j.canlet.2025.217986_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.canlet.2025.217986_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38023","article-title":"Immune checkpoint blockade and CAR T-cell therapy in T-cell\/histiocyte-rich large B-cell lymphoma: challenges and opportunities","volume":"10","author":"Sahin","year":"2024","journal-title":"Heliyon"},{"issue":"8034","key":"10.1016\/j.canlet.2025.217986_bib48","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2025.217986_bib49","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-Positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.canlet.2025.217986_bib50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2025.217986_bib52","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2025.217986_bib53","doi-asserted-by":"crossref","DOI":"10.2174\/0115665232357078250331180413","article-title":"CRISPR\/Cas9 technology for modifying immune checkpoint in CAR-T cell therapy for hematopoietic malignancies","author":"Shams","year":"2025","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.canlet.2025.217986_bib54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.reth.2022.09.009","article-title":"CRISPR\/Cas9 and AAV mediated insertion of \u03b22 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy","volume":"21","author":"Meshitsuka","year":"2022","journal-title":"Regen Ther."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2025.217986_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202300880","article-title":"Advanced materials and delivery systems for enhancement of chimeric antigen receptor cells","volume":"7","author":"Li","year":"2023","journal-title":"Small Methods"},{"key":"10.1016\/j.canlet.2025.217986_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.795164","article-title":"Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero?","volume":"13","author":"Safarzadeh Kozani","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3348\/kjr.2022.0814","article-title":"Prostatic artery embolization: an update","volume":"24","author":"Bilhim","year":"2023","journal-title":"Korean J. Radiol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib60","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217986_bib61","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2025.217986_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.ircmb.2022.03.004","article-title":"Enabling CAR-T cells for solid tumors: rage against the suppressive tumor microenvironment","volume":"370","author":"Anto\u00f1ana-Vildosola","year":"2022","journal-title":"Int. Rev. Cell. Mol. Biol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib63","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/cancers15041026","article-title":"The receptor for advanced glycation endproducts (RAGE) and its ligands S100A8\/A9 and high mobility group box protein 1 (HMGB1) are key regulators of myeloid-derived suppressor cells","volume":"15","author":"Ostrand-Rosenberg","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.canlet.2025.217986_bib64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41585-021-00488-8","article-title":"The potential of CAR T cell therapy for prostate cancer","volume":"18","author":"Wolf","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19147","article-title":"Chimeric antigen receptor-modified T cells therapy in prostate cancer: a comprehensive review on the current state and prospects","volume":"9","author":"He","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.canlet.2025.217986_bib67","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217986_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231170474","article-title":"The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review","volume":"15","author":"Martin","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2025.217986_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104556","article-title":"Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors","volume":"205","author":"Puik","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217986_bib71","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217986_bib72","article-title":"Targeting the tumour cell surface in advanced prostate cancer","volume":"1","author":"Boixareu","year":"2025","journal-title":"Nat. Rev. Urol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib73","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/cancers15051412","article-title":"Bispecific T-Cell engagers therapies in solid tumors: focusing on prostate cancer","volume":"15","author":"Sim\u00e3o","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.canlet.2025.217986_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","article-title":"Expression, and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?","volume":"39","author":"Gires","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"48","key":"10.1016\/j.canlet.2025.217986_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib76","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1186\/s12885-018-5010-5","article-title":"Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy\/radiotherapy response in vivo","volume":"18","author":"Ni","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer - beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"issue":"16","key":"10.1016\/j.canlet.2025.217986_bib78","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217986_bib79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J. Neuro Oncol."},{"issue":"14","key":"10.1016\/j.canlet.2025.217986_bib80","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib81","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12967-016-0791-2","article-title":"Melanoma and immunotherapy bridge 2015 : naples, Italy. 1-5 December 2015","volume":"14","author":"Nanda","year":"2016","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib82","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol."},{"issue":"36","key":"10.1016\/j.canlet.2025.217986_bib83","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-Directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217986_bib84","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2025.217986_bib85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-019-14219-6","article-title":"MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer","volume":"11","author":"Yasumizu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12935-021-02398-6","article-title":"Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"12","key":"10.1016\/j.canlet.2025.217986_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137112","article-title":"MUC1-C drives stemness in progression of colitis to colorectal cancer","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"issue":"159","key":"10.1016\/j.canlet.2025.217986_bib89","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0149-2020","article-title":"The role of mucin 1 in respiratory diseases","volume":"30","author":"Ballester","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/biom15020275","article-title":"The oncoprotein mucin 1 in pancreatic cancer onset and progression: potential clinical implications","volume":"15","author":"Dieli","year":"2025","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.canlet.2025.217986_bib91","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/pmic.200800040","article-title":"Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior","volume":"8","author":"Yonezawa","year":"2008","journal-title":"Proteomics"},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/pcan.2012.49","article-title":"Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer","volume":"16","author":"Sanchez","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"10","key":"10.1016\/j.canlet.2025.217986_bib93","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present, and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-020-00405-z","article-title":"Preclinical development of CD126 CAR-T cells with broad antitumor activity","volume":"11","author":"Mishra","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2025.217986_bib95","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0303-7207(02)00263-0","article-title":"Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth","volume":"197","author":"Culig","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib96","article-title":"Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells","volume":"5","author":"Yoshikawa","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib97","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib99","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.canlet.2025.217986_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415827","article-title":"Diverse neutrophil functions in cancer and promising neutrophil-based cancer therapies","volume":"23","author":"Sounbuli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib101","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/cells10061270","article-title":"Mast cells: a new frontier for cancer immunotherapy","volume":"10","author":"Lichterman","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib102","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217986_bib103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.smim.2017.09.001","article-title":"Tailoring natural killer cell immunotherapy to the tumour microenvironment","volume":"31","author":"Barrow","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.canlet.2025.217986_bib104","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2015.00601","article-title":"Natural killer cell immunomodulation: targeting activating, inhibitory, and Co-stimulatory receptor signaling for cancer immunotherapy","volume":"6","author":"Chester","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.217986_bib105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","article-title":"Natural killer cell-mediated immunosurveillance of human cancer","volume":"31","author":"Malmberg","year":"2017","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib106","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1172\/JCI200422206","article-title":"Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer","volume":"114","author":"Wu","year":"2004","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib107","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2025.217986_bib108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jim.2009.06.004","article-title":"Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients","volume":"348","author":"Gannon","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s40425-019-0693-y","article-title":"Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1\/PD-L1 blockade therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib110","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1602133","article-title":"Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci. Adv."},{"issue":"537","key":"10.1016\/j.canlet.2025.217986_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3577","article-title":"Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer","volume":"12","author":"Subudhi","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib112","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-Engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib113","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2025.217986_bib114","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.217986_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"656","key":"10.1016\/j.canlet.2025.217986_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217986_bib117","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Contr. Release"},{"issue":"7\u20138","key":"10.1016\/j.canlet.2025.217986_bib118","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41417-018-0062-x","article-title":"Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors","volume":"27","author":"Golinelli","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2025.217986_bib119","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2021.10.041","article-title":"A highly-specific fully-human antibody and CAR-T cells targeting CD66e\/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo","volume":"525","author":"Baek","year":"2022","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.217986_bib122","article-title":"Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates","volume":"13","author":"Kim","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217986_bib123","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","article-title":"CEACAM5-Targeted Immuno-PET in androgen receptor-negative prostate cancer","volume":"65","author":"Imberti","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"45","key":"10.1016\/j.canlet.2025.217986_bib125","doi-asserted-by":"crossref","first-page":"74189","DOI":"10.18632\/oncotarget.12404","article-title":"Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells \"in vitro\" and correlating with progression \"in vivo\"","volume":"7","author":"Perico","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23, and PSMA-Targeted duo-CAR T cells in prostate cancer eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J. Transl. Med."},{"issue":"7906","key":"10.1016\/j.canlet.2025.217986_bib127","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib128","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib129","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.canlet.2025.217986_bib130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of Anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib131","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-Targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.canlet.2025.217986_bib132","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf0108","article-title":"\u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer","volume":"9","author":"Frieling","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib133","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy","volume":"18","author":"Hu","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib134","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3724\/abbs.2023092","article-title":"Advances in landscape and related therapeutic targets of the prostate tumor microenvironment","volume":"55","author":"Li","year":"2023","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.canlet.2025.217986_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200646","article-title":"Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy","volume":"13","author":"Czajka-Francuz","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib136","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin. Immunopathol."},{"issue":"25","key":"10.1016\/j.canlet.2025.217986_bib137","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41388-025-03458-1","article-title":"Immunometabolism of regulatory T cells in cancer","volume":"44","author":"Saravia","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib138","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers : the \"all-around warrior\" in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib139","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s12276-021-00568-0","article-title":"Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion","volume":"53","author":"Seo","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib140","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.canlet.2025.217986_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib142","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","article-title":"Engineering enhanced CAR T-cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib143","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217986_bib144","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib145","article-title":"Discovery and validation of human genomic safe harbor sites for gene and cell therapies","volume":"2","author":"Aznauryan","year":"2022","journal-title":"Cell Rep. Methods"},{"issue":"11","key":"10.1016\/j.canlet.2025.217986_bib146","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1042\/BCJ20170793","article-title":"CRISPR base editors: genome editing without double-stranded breaks","volume":"475","author":"Eid","year":"2018","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.canlet.2025.217986_bib147","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13287-022-02819-x","article-title":"Hurdles to breakthrough in CAR T cell therapy of solid tumors","volume":"13","author":"Marofi","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.canlet.2025.217986_bib148","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41416-021-01315-y","article-title":"AMD3100\/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells","volume":"125","author":"Fearon","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2025.217986_bib149","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3390\/cancers16193410","article-title":"Tumor-associated macrophages as major immunosuppressive cells in the tumor microenvironment","volume":"16","author":"Ghebremedhin","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.canlet.2025.217986_bib150","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.canlet.2025.217986_bib151","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41434-023-00404-2","article-title":"RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells","volume":"30","author":"Bouquet","year":"2023","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.canlet.2025.217986_bib152","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2025.217986_bib153","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.canlet.2025.217986_bib154","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cancers13153912","article-title":"Treatment-related adverse events of chimeric antigen receptor T-Cell (CAR T) in clinical trials: a systematic review and meta-analysis","volume":"13","author":"Lei","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.canlet.2025.217986_bib155","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare utilization and cost trends for CAR T cell therapies across settings of care in the treatment of diffuse large B-Cell lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:36:43Z","timestamp":1772804203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":155,"alternative-id":["S0304383525005567"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217986","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217986"}}